SCHEMBL7250734

SCHEMBL7250734

NC(=O)c1cc2c(COc3ccc(Cl)c(F)c3)cncc2s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ICAM1 P05362 16/20 0.69
▸ SELE P16581 16/20 0.69
▸ VCAM1 P19320 8/20 0.56
▸ CCNC P24863 3/20 0.52
▸ CDK8 P49336 3/20 0.52
▸ CCNT1 O60563 1/20 0.52
▸ CDK9 P50750 1/20 0.52
▸ ROCK2 O75116 3/20 0.50
▸ CDK1 P06493 3/20 0.50
▸ PIM1 P11309 3/20 0.50
▸ PRKACA P17612 3/20 0.50
▸ CDK2 P24941 3/20 0.50
▸ FLT4 P35916 3/20 0.50
▸ CSNK1D P48730 3/20 0.50
▸ GSK3A P49840 3/20 0.50
▸ GSK3B P49841 3/20 0.50
▸ PLK1 P53350 3/20 0.50
▸ CDK5 Q00535 3/20 0.50
▸ PRKCD Q05655 3/20 0.50
▸ DYRK1A Q13627 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7250679 0.86 ICAM1 (0.66) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7054474 0.82 ICAM1 (1.00) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7255481 0.81 ICAM1 (0.69) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7797352 0.80 ICAM1 (0.69) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7931907 0.79 ICAM1 (0.72) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7855096 0.78 CDK1 (0.54) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7797360 0.76 ICAM1 (0.55) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7642734 0.75 ICAM1 (0.64) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7846850 0.75 ICAM1 (0.74) ICAM1SELEVCAM1CCNCCDK8
SCHEMBL7054697 0.74 ICAM1 (1.00) ICAM1SELEVCAM1CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579882-B2 Thieno(2,3-d)pyrimidine derivatives ABBOTT LABORATORIES 2003-06-17 — — US disclosed
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ABBVIE INC. 2001-09-06 — — US disclosed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 — — EP disclosed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM ICAM1 1/4885SELE 16/4885VCAM1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback